RegenoCELL Therapeutics, Inc. (OTC BB: RCLL) will be among the first companies to bring stem cell therapy treatments to the market. Our treatments for Congestive Heart Failure and Peripheral Artery Disease provide hope for patients who have until now been given limited options or none. These revolutionary treatments restore life to our patients.
RCLL is utilizing adult stem cells, those derived from the patient's own blood, which eliminates the ethical and safety concerns associated with embryonic and umbilical cord blood stem cells. Stem cells have the ability to produce other cells identical to themselves or to differentiate into specific cell lineages which can be used in the regeneration and repair of damaged tissue.